Team
Team

Jörn Weisner, Dr. rer. nat

Position: Postdoctoral Fellow

Room no.: CP-02-114

Telephone no.: +49 231 755 7052

Member of the group since: 05/2013

University degree: Dr. rer. nat. in Chemical Biology, TU Dortmund University

 

Expertise: protein biochemistry, mammalian cell culture, assay development

Off-Lab activities (hobbies): football, music, food

 

Earlier positions:

Bachelor studies at the MPI of Molecular Physiology with Dr. Christina-Maria Hecker in the department of Prof. Philippe Bastiaens on the pheromone response pathway in yeast using fluorescence cross-correlation spectroscopy.

 

Publications:

  1. Lategahn, J.; Hardick, J.; Grabe, T.; Niggenaber, J.; Jeyakumar, K.; Keul, M.; Tumbrink, H. L.; Becker, C.; Hodson, L.; Kirschner, T.; Klövekorn, P.; Ketzer, J.; Baumann, M.; Terheyden, S.; Unger, A.; Weisner, J.; Müller, M. P.; van Otterlo, W. A. L.; Bauer, S.; Rauh, D.. Targeting Her2-insYVMA with Covalent Inhibitors-A Focused Compound Screening and Structure-Based Design Approach. J. Med. Chem. 2020, 63 (20), 11725–11755.

    DOI PubMed

  2. Roser, P.; Weisner, J.; Stehle, J.; Rauh, D.; Drescher, M.. Conformational selection vs. induced fit: insights into the binding mechanisms of p38α MAP Kinase inhibitors. Chem. Commun. 2020, 56 (62), 8818–8821.

    DOI PubMed

  3. a) Quambusch, L.; Landel, I.; Depta, L.; Weisner, J.; Uhlenbrock, N.; Müller, M. P.; Glanemann, F.; Althoff, K.; Siveke, J. T.; Rauh, D.. Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity. Angew. Chem. Int. Ed. Engl. 2019, 58 (52), 18823–18829.

    DOI PubMed

    b) Quambusch, L.; Landel, I.; Depta, L.; Weisner, J.; Uhlenbrock, N.; Müller, M. P.; Glanemann, F.; Althoff, K.; Siveke, J. T.; Rauh, D.. Covalent‐Allosteric Inhibitors to Achieve Akt Isoform‐Selectivity. Angew. Chem. 2019, 131 (52), 18999–19005.

    DOI

  4. Schehr, M.; Ianes, C.; Weisner, J.; Heintze, L.; Müller, M. P.; Pichlo, C.; Charl, J.; Brunstein, E.; Ewert, J.; Lehr, M.; Baumann, U.; Rauh, D.; Knippschild, U.; Peifer, C.; Herges, R.. 2-Azo-, 2-diazocine-thiazols and 2-azo-imidazoles as photoswitchable kinase inhibitors: limitations and pitfalls of the photoswitchable inhibitor approach. Photochem. Photobiol. Sci. 2019, 18 (6), 1398–1407.

    DOI PubMed

  5. Uhlenbrock, N.; Smith, S.; Weisner, J.; Landel, I.; Lindemann, M.; Le, T. A.; Hardick, J.; Gontla, R.; Scheinpflug, R.; Czodrowski, P.; Janning, P.; Depta, L.; Quambusch, L.; Müller, M. P.; Engels, B.; Rauh, D.. Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt. Chem. Sci. 2019, 10 (12), 3573–3585.

    DOI PubMed

  6. Weisner, J.; Landel, I.; Reintjes, C.; Uhlenbrock, N.; Trajkovic-Arsic, M.; Dienstbier, N.; Hardick, J.; Ladigan, S.; Lindemann, M.; Smith, S.; Quambusch, L.; Scheinpflug, R.; Depta, L.; Gontla, R.; Unger, A.; Müller, H.; Baumann, M.; Schultz-Fademrecht, C.; Günther, G.; Maghnouj, A.; Müller, M. P.; Pohl, M.; Teschendorf, C.; Wolters, H.; Viebahn, R.; Tannapfel, A.; Uhl, W.; Hengstler, J. G.; Hahn, S. A.; Siveke, J. T.; Rauh, D.. Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in KRAS-Mutant Pancreatic and Colorectal Cancer. Cancer Res. 2019, 79 (9), 2367–2378.

    DOI PubMed

  7. Roser, P.; Weisner, J.; Simard, J. R.; Rauh, D.; Drescher, M.. Direct monitoring of the conformational equilibria of the activation loop in the mitogen-activated protein kinase p38α. Chem. Commun. 2018, 54 (85), 12057–12060.

    DOI PubMed

  8. Wiedemann, B.; Weisner, J.; Rauh, D.. Chemical modulation of transcription factors. Med. Chem. Commun. 2018, 9 (8), 1249–1272.

    DOI PubMed

  9. Wolle, P.; Weisner, J.; Keul, M.; Landel, I.; Lategahn, J.; Rauh, D.. RASPELD to Perform High-End Screening in an Academic Environment toward the Development of Cancer Therapeutics. ChemMedChem 2018, 13 (19), 2065–2072.

    DOI PubMed

  10. a) Bührmann, M.; Hardick, J.; Weisner, J.; Quambusch, L.; Rauh, D.. Covalent Lipid Pocket Ligands Targeting p38α MAPK Mutants. Angew. Chem. Int. Ed. Engl. 2017, 56 (43), 13232–13236.

    DOI PubMed

    b) Bührmann, M.; Hardick, J.; Weisner, J.; Quambusch, L.; Rauh, D.. Kovalente Liganden zur Adressierung einer lipophilen Bindetasche in der MAPK p38 α. Angew. Chem. 2017, 129 (43), 13415–13419.

    DOI

  11. Rauh, D.; Gontla, R.; Weisner, J. Kinase Inhbitors And Their Use In Cancer Therapy. European Patent EP 20150166458 20150505, May 5, 2015.
  12. a) Weisner, J.; Gontla, R.; van der Westhuizen, L.; Oeck, S.; Ketzer, J.; Janning, P.; Richters, A.; Mühlenberg, T.; Fang, Z.; Taher, A.; Jendrossek, V.; Pelly, S. C.; Bauer, S.; van Otterlo, W. A. L.; Rauh, D.. Covalent-Allosteric Kinase Inhibitors. Angew. Chem. Int. Ed. Engl. 2015, 54 (35), 10313–10316.

    DOI PubMed

    b) Weisner, J.; Gontla, R.; van der Westhuizen, L.; Oeck, S.; Ketzer, J.; Janning, P.; Richters, A.; Mühlenberg, T.; Fang, Z.; Taher, A.; Jendrossek, V.; Pelly, S. C.; Bauer, S.; van Otterlo, W. A. L.; Rauh, D.. Kovalent-allosterische Kinase-Inhibitoren. Angew. Chem. 2015, 127 (35), 10452–10456.

    DOI